Безопасность и взаимодействие прямых пероральных антикоагулянтов с антиаритмическими препаратами

Использование прямых пероральных антикоагулянтов (ПОАК) (пероральные антикоагулянты, не являющиеся антагонистами витамина K) минимизировало риски, связанные с антагонистом витамина K (варфарином). В настоящее время ПОАК имеют приоритет по сравнению с варфарином для профилактики тромбоэмболических осложнений у пациентов с фибрилляцией предсердий (ФП) и рядом других состояний, требующих антикоагулянтной терапии. ПОАК, наряду с антиаритмической терапией, являются принятой стратегией лечения ФП. В то же время до конца не выяснено влияние межлекарственных взаимодействий (МЛВ) между ПОАК и антиаритмическими препаратами (ААП), имеющими общие точки метаболического приложения. Чтобы обеспечить эффективную и безопасную антикоагулянтную и антиаритмическую терапию у пациентов с ФП, важно понять механизмы и степень выраженности МЛВ ПОАК и ААП различных классов. В данном обзоре обсуждаются вопросы МЛВ ПОАК и ААП, использующихся для лечения ФП.

1. Reiffel JA, Weitz JI, Reilly P, et al. DOAC monitoring, reversal agents, and postapproval safety and effectiveness evaluation: a cardiac safety research consortium think tank. Cardiac safety research consortium presenters and participants. Am Heart J. 2016;177:74-86. doi:10.1016/j.ahj.2016.04.010.

2. Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015;35(5):1056-65. doi:10.1161/ATVBAHA.115.303397.

3. Kundu A, Sardar P, Chatterjee S, et al. Minimizing the risk of bleeding with DOACs in the elderly. Drugs Aging. 2016;33(7):491-500. doi:10.1007/s40266-016-0376-z.

4. Eikelboom J, Merli G. Bleeding with direct oral anticoagulants vs warfarin: clinical experience. Am J Med. 2016;129(11S):S33-40. doi:10.1016/j.amjmed.2016.06.003.

5. Whitworth MM, Haase KK, Fike DS, et al. Utilization and prescribing patterns of direct oral anticoagulants. Int J Gen Med. 2017;10:87-94. doi:10.2147/IJGM.S129235.

6. Voukalis C, Lip GY, Shantsila E. Drug-drug interactions of nonvitamin K oral anticoagulants. Expert Opin Drug Metab Toxicol. 2016;12(12):1445-61. doi:10.1080/17425255.2016.1225037.

7. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmcol Ther. 2013;138:103-41. doi:10.1016/j.pharmthera.2012.12.007.

8. Megan R, Obaidat A, Hogenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165:1260-87. doi:10.1111/j.1476-5381.2011.01724.x.

9. Lee CA, O'Connor MA, Ritchie TK, et al. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. Drug Metab Dispos. 2015;43:490-9. doi:10.1124/dmd.114.06217.

10. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997;29(1-20):413-580. doi:10.3109/03602539709037591.

11. Dan GA, Antoni Martinez-Rubio A, Agewal S, et al. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018;20(5):731-2an. doi:10.1093/europace/eux373.

12. Herink MC, Zhuo YF, Williams CD, et al. Clinical management of pharmacokinetic drug interactions with direct oral anticoagulants (DOACs). Drugs. 2019;79(15):1625-34. doi:10.1007/s40265-019-01183-0.

13. Zimetbaum P. Antiarrhythmic Drug Therapy for Atrial Fibrillation. Circulation. 2012;125:381-9. doi:10.1161/CIRCULATIONAHA.111.019927.

14. Ahrens I, Peter K, Lip GY, et al. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. Discov Med. 2012;13(73):445-50.

15. Wessler J, Grip L, Mendell J, et al. The P-Glycoprotein Transport System and Cardiovascular Drugs. J Am Coll Card. 2013;61:2495. doi:10.1016/j.jacc.2013.02.058.

16. Groenendaal D, Strabach G, Garcia-Hernandez A, et al. The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein. Clin Pharmacol Drug Dev. 2014;3(3):194-201. doi:10.1111/j.1365-2125.2012.04346.x.

17. Wiggins BS, Dixon DL, Neyens RR, et al. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75(11):1341-50. doi:1016/j.jacc.2019.12.068.

18. Mendell J, Zahir H, Ridout G, et al. Drug-drug interaction studies of cardiovascular drugs (amiodarone, digoxin, quinidine, atorvastatin and verapamil) involving P-glycoprotein (P-gp), an efflux transporter, on the pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor (abstr). J Am Coll Cardiol. 2011;57:E1510. doi:10.1016/S0735-1097(11)61510-6.

19. Rodriques AD. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the “rank order” approach. Drug Metab Lett. 2007;1:31-5. doi:10.2174/187231207779814247.

20. Konieczny K, Dorian P. Clinically Important Drug-Drug Interactions Between Antiarrhythmic Drugs and Anticoagulants. J Innov Cardiac Rhythm Manage. 2019;10(3):3552-9. doi:10.19102/icrm.2019.100304.

21. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. 2018 edition. Toronto, Canada: Canadian Pharmacists Association. ISBN: 1772410047 (ISBN13: 9781772410044).

22. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507. doi:10.1093/europace/euv309.

23. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330-93. doi:10.1093/eurheartj/ehy136.

24. Dabigatran etexilate mesylate (Pradaxa) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, 2018.

25. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-75. doi:10.1111/j.1538-7836.2011.04498.x.

26. Kubitza D, Becka M, Roth A, et al. Absence of clinically relevant interactions between rivaroxaban — an oral, direct Factor Xa inhibitor — and digoxin or atorvastatin in healthy subjects. J Int Med Res. 2012;40(5):1688-707. doi:10.1177/030006051204000508.

27. Lupercio L, Romero J, Peltzer B, et al. Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. Am J Med. 2018;131(5):573.e1-e8. doi:10.1016/j.amjmed.2017.11.047.

28. Hartter S, Sennewald R, Nehmiz G, et al. Oral bioavailability of dabigatran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75:1053-62. doi:10.1111/j.1365-2125.2012.04453.x.

29. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2012;75:476-87. doi:10.1111/j.1365-2125.2012.04369.x.

30. Kim M, Son H, Noh K, et al. Effects of Verapamil and Diltiazem on the pharmacokinetics and pharmacodynamics of rivaroxaban. Pharmaceutics. 2019;11:E133. doi:10.3390/pharmaceutics11030133.

31. Hanigan S, Das J, Pogue K, et al. The Real World Use of Combined P-glycoprotein and Moderate CYP3A4 Inhibitors With Rivaroxaban or Apixaban Increases Bleeding. J Thromb Thrombolysis. 2020;49(4):636-43. doi:10.1007/s11239-020-02037-3.

32. Turakhia MP, Blankestijn PJ, Carrero JJ, et al. Chronic kidney disease and arrhythmias: conclusions froma Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018;39:2314-25. doi:10.1093/eurheartj/ehy060.

33. Caldeira D, Barra M, Santos AT, et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014;100(7):550-6. doi:10.1136/heartjnl-2013-305288.

34. Khoury T, Ayman AR, Cohen J, et al. The complex role of anticoagulation in cirrhosis: an updated review of where we are and where we are going. Digestion. 2016;93(2):149-59. doi:10.1159/000442877.

35. Liakoni E, Ratz Bravo AE, Krahenbuhl S. Hepatotoxicity of new oral anticoagulants (DOACs). Drug Saf. 2015;38(8):711-20. doi:10.1007/s40264-015-0317-5.

36. Mekaj YH, Mekaj AY, Duci SB, et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;24(11):967-77. doi:10.2147/TCRM.S84210.